Champignon Forms North American Clinical Expansion Committee
04 Mai 2020 - 2:00PM
Champignon Brands Inc. (“
Champignon” or the
“
Company”)
(CSE: SHRM) (FWB: 496) (OTCQB:
SHRMF), a human optimization sciences company focused on
applying novel and natural treatment protocols to address a broad
range of disorders and deficiencies with an emphasis on psychedelic
medicine, has advanced its North American new clinical entity (NCE)
expansion stratagem via the formation of a dedicated planning
committee (the “
Committee”).
The Committee has been mandated with accelerating
the Company’s entry into the U.S., where it plans to open and/or
acquire a minimum of five NCEs during 2020. Champignon continues to
conduct discussions with revenue generating clinics located in
California, New York, Pennsylvania, Texas, Florida and
Missouri.
“We will look to capitalize on the fragmented
nature of the U.S. ketamine clinic marketplace with the objective
of creating a consortium of integrated mood disorder treatment and
research facilities,” commented Gareth Birdsall, CEO of Champignon.
“By leveraging existing protocols, data sets and SOPs from our
flagship clinic, the Canadian Rapid Treatment Centre of Excellence,
arguably the most advanced integrated mood disorder centre in North
America, we will improve economics, increase patient enrollment and
function as the pre-eminent brick and mortar staging ground for
novel molecule discovery initiatives. Champignon remains bullish on
the U.S. marketplace due to favourable co-payer infrastructure, as
well as a vast addressable patient population.”
About Champignon Brands Inc.
Champignon Brands (CSE: SHRM) is focused on the
formulation and manufacturing of novel ketamine, anaesthetics and
adaptogenic delivery platforms for the nutraceutical and
psychedelic medicine while being supported by a leading
psychedelics medicines clinic platform. The Company is pursuing the
development and commercialization of rapid onset treatments capable
of improving health outcomes, such as depression and post-traumatic
stress disorder (PTSD), as well as substance and alcohol use
disorders. Under a collaborative research agreement with the
University of Miami's Miller School of Medicine, the Company is
conducting preclinical studies and eventual human clinical trials,
with the objective of demonstrating safety and efficacy of the
combination of psilocybin and cannabidiol in treating mTBI with
PTSD or stand-alone PTSD. Champignon continues to be inspired by
sustainability, as its medicinal mushroom-infused SKUs are organic,
non-GMO and vegan certified. For more information, visit the
Company’s website at: https://champignonbrands.com/.
ON BEHALF OF THE BOARD OF DIRECTORS
W. Gareth Birdsall CEO & DirectorT:
+1 (613) 967-9655E: info@champignonbrands.com
FOR INVESTOR INQUIRIES:
Tyler Troup Circadian Group
E: SHRM@champignonbrands.com
FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:
Remy ScalabriniMaricom Inc.E: rs@maricom.ca T:
(888) 585-MARI
The CSE and Information Service Provider have not
reviewed and does not accept responsibility for the accuracy or
adequacy of this release.
Forward-looking Information Cautionary
Statement
Except for statements of historic fact, this
news release contains certain "forward-looking information" within
the meaning of applicable securities law. Forward-looking
information is frequently characterized by words such as "plan",
"expect", "project", "intend", "believe", "anticipate", "estimate"
and other similar words, or statements that certain events or
conditions "may" or "will" occur. Forward-looking statements are
based on the opinions and estimates at the date the statements are
made, and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those anticipated in the forward-looking statements
including, but not limited to delays or uncertainties with
regulatory approvals, including that of the CSE. There are
uncertainties inherent in forward-looking information, including
factors beyond the Company’s control. There are no assurances that
the business plans for Champignon Brands described in this news
release will come into effect on the terms or time frame described
herein. The Company undertakes no obligation to update
forward-looking information if circumstances or management's
estimates or opinions should change except as required by law. The
reader is cautioned not to place undue reliance on forward-looking
statements. Additional information identifying risks and
uncertainties that could affect financial results is contained in
the Company’s filings with Canadian securities regulators, which
are available at www.sedar.com.
Champignon Brands (CSE:SHRM)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Champignon Brands (CSE:SHRM)
Historical Stock Chart
Von Dez 2023 bis Dez 2024